News Johnson & Johnson back in 'exclusive' talks to buy Actelion Deal expected to be worth around $30 billion.
News BIND accepts Pfizer bid following bankruptcy Bid of $20 million may be enough to acquire all of BIND's assets.
Articles Celgene’s new CEO weighs in to drug pricing debate Celgene's new CEO Mark Alles discusses pricing and M&A, criticises Valeant's approach. Richard Staines reports.
Articles Pharma news round-up: Pfizer-Allergan merger scrapped, Gilea... A round-up of this week's top pharma and healthcare news – plus reaction from social media. Marco Ricci reports.
Articles UCB: growing sales and growing bones The specialist pharma company is set to expand into osteoporosis through its partnership with Amgen
News Iambic prices its IPO, seeking to raise up to $160m AI-powered drug discovery company Iambic Therapeutics has announced the terms of its Nasdaq IPO, pitching at a valuation of more than $800m.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
